

Appl. No. : [REDACTED] 09/782,816  
Filed : February 14, 2001

Remarks

The amendments in the specification are of formal nature and serve to ensure conformation of the representations for the amino acids in the specification to the currently filed Sequence Listing. The amendments do not add new matter.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendments. The attached page is captioned "Version with markings to show changes made."

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: May 30, 2001

By: Ginger R. Dreger  
Ginger R. Dreger  
Registration No. 33,055  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660

Appl. No.

Filed

: 09/782,816

: February 14, 2001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the specification:**

The paragraph beginning at page 3, line 21, has been amended as follows:

--In one aspect, the invention concerns an isolated peptide selected from the group consisting of:

(X1)<sub>n</sub>EVEKIKTTVKESATEEKLTPV[X2]XaaL(X2)<sub>m</sub> (SEQ ID NO: 1),

(Y1)<sub>n</sub>EVAALQVDRKVADEEKQSYDAV(Y2)<sub>m</sub> (SEQ ID NO: 2),

wherein

n and m independently represent 0 or 1, and Xaa is V or L;

X1[, X2 and X3] and X2 are independently defined as follows

X1 is GVKETPQQKYQRLLHEVQELTT (SEQ ID NO: 3), or

VKETPQQKYQRLLHEVQELTT (SEQ ID NO: 4), or

KETPQQKYQRLLHEVQELTT (SEQ ID NO: 5) or,

ETPQQKYQRLLHEVQELTT (SEQ ID NO: 6) or,

TPQQKYQRLLHEVQELTT (SEQ ID NO: 7) or,

PQQKYQRLLHEVQELTT (SEQ ID NO: 8) or,

QQKYQRLLHEVQELTT (SEQ ID NO: 9) or,

QKYQRLLHEVQELTT (SEQ ID NO: 10) or,

KYQRLLHEVQELTT (SEQ ID NO: 11) or,

YQRLLHEVQELTT (SEQ ID NO: 12) or,

QRLLHEVQELTT (SEQ ID NO: 13) or,

RLLHEVQELTT (SEQ ID NO: 14) or,

LLHEVQELTT (SEQ ID NO: 15) or,

LHEVQELTT (SEQ ID NO: 16) or,

HEVQELTT (SEQ ID NO: 17) or,

EVQELTT (SEQ ID NO: 18) or,

VQELTT (SEQ ID NO: 19) or,

QELTT (SEQ ID NO: 20) or,

ELTT (SEQ ID NO: 21), or

Appl. No. : 09/782,816  
Filed : February 14, 2001

LT, or

TT, or

T;

[X2 is V or L,] and

[X3] X2 is AKQLAAL (SEQ ID NO: 22), or

AKQLAA (SEQ ID NO: 23), or

AKQLA (SEQ ID NO: 24), or

AKQL (SEQ ID NO: 25), or

AKQ, or

AK, or

A;

and

Y1 and Y2 are independently defined as follows

Y1 is GEKETPVQKCQRLQIEMNELLN (SEQ ID NO: 26), or

EKETPVQKCQRLQIEMNELLN (SEQ ID NO: 27), or

KETPVQKCQRLQIEMNELLN (SEQ ID NO: 28), or

ETPVQKCQRLQIEMNELLN (SEQ ID NO: 29), or

TPVQKCQRLQIEMNELLN (SEQ ID NO: 30), or

PVQKCQRLQIEMNELLN (SEQ ID NO: 31), or

VQKCQRLQIEMNELLN (SEQ ID NO: 32), or

QKCQRLQIEMNELLN (SEQ ID NO: 33), or

KCQRLQIEMNELLN (SEQ ID NO: 34), or

CQRLQIEMNELLN (SEQ ID NO: 35), or

QRLQIEMNELLN (SEQ ID NO: 36), or

RLQIEMNELLN (SEQ ID NO: 37), or

LQIEMNELLN (SEQ ID NO: 38), or

QIEMNELLN (SEQ ID NO: 39), or

IEMNELLN (SEQ ID NO: 40), or

EMNELLN (SEQ ID NO: 41), or

MNELLN (SEQ ID NO: 42), or

NELLN (SEQ ID NO: 43), or

Appl. No.

Filed

: 09/782,816

: February 14, 2001

ELLN (SEQ ID NO: 44), or

LLN, or

LN, or

N; and

Y2 is VATVISTAR (SEQ ID NO: 45), or

VATVISTA (SEQ ID NO: 46), or

VATVIST (SEQ ID NO: 47), or

VATVIS (SEQ ID NO: 48), or

VATVI (SEQ ID NO: 49), or

VATV (SEQ ID NO: 50), or

VAT, or

VA, or

V, and

derivatives thereof having at least about 90% identity with SEQ ID NO: 1 or SEQ ID NO: 2.--

The paragraph beginning at page 5, line 31, has been amended as follows:

--In a preferred embodiment, the peptide has one of the following sequences: **GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPV**[X2]XaaLAKQ LAAL (SEQ ID NO: 51), where [X2] Xaa is as defined above, or **GEKETPVQKCQRLQIEMNELLNEVAALQVDRKVADEEKQSYDAVVATVISTAR** (SEQ ID NO: 52), or has at least about 75%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, most preferably at least about 95% identity with one of these sequences. Preferably, the peptide variants contain only conservative amino acid substitutions compared to the reference peptide sequences.--

The paragraph beginning at page 7, line 4, has been amended as follows:

--Figure 1 is the amino acid sequence of human p50 (SEQ ID NO: 53), wherein the peptide of SEQ ID NO: 51 ([X2] Xaa is L) is bolded and underlined.--

Appl. No.

: 09/782,816

Filed

: February 14, 2001

The paragraph beginning at page 7, line 6, has been amended as follows:

-- Figure 2 is the partial amino acid sequence of mouse p50 (SEQ ID NO: 54), wherein the peptide of SEQ ID NO: 51 ([X2] Xaa is V) is bolded and underlined.--

**In the claims:**

Claims 1 and 2 have been amended as follows:

1(Amended). An isolated peptide selected from the group consisting of:

(X1)<sub>n</sub>EVEKIKTTVKESATEEKLTPV[X2]XaaL(X2)<sub>m</sub> (SEQ ID NO: 1),

(Y1)<sub>n</sub>EVAALQVDRKVADEEKQSYDAV(Y2)<sub>m</sub> (SEQ ID NO: 2),

wherein

n and m independently represent 0 or 1, and Xaa is V or L;

X1[, X2 and X3] and X2 are independently defined as follows

X1 is GVKETPQQKYQRLLHEVQELTT (SEQ ID NO: 3), or

VKETPQQKYQRLLHEVQELTT (SEQ ID NO: 4), or

KETPQQKYQRLLHEVQELTT (SEQ ID NO: 5) or,

ETPQQKYQRLLHEVQELTT (SEQ ID NO: 6) or,

TPQQKYQRLLHEVQELTT (SEQ ID NO: 7) or,

PQQKYQRLLHEVQELTT (SEQ ID NO: 8) or,

QQKYQRLLHEVQELTT (SEQ ID NO: 9) or,

QKYQRLLHEVQELTT (SEQ ID NO: 10) or,

KYQRLLHEVQELTT (SEQ ID NO: 11) or,

YQRLLHEVQELTT (SEQ ID NO: 12) or,

QRLLHEVQELTT (SEQ ID NO: 13) or,

RLLHEVQELTT (SEQ ID NO: 14) or,

LLHEVQELTT (SEQ ID NO: 15) or,

LHEVQELTT (SEQ ID NO: 16) or,

HEVQELTT (SEQ ID NO: 17) or,

EVQELTT (SEQ ID NO: 18) or,

VQELTT (SEQ ID NO: 19) or,

QELTT (SEQ ID NO: 20) or,

Appl. No.  
Filed

: 09/782,816  
: February 14, 2001  
ELTT (SEQ ID NO: 21), or

LT, or

TT, or

T;

[X2 is V or L,] and

[X3] X2 is AKQLAAL (SEQ ID NO: 22), or

AKQLAA (SEQ ID NO: 23), or

AKQLA (SEQ ID NO: 24), or

AKQL (SEQ ID NO: 25), or

AKQ, or

AK, or

A;

and

Y1 and Y2 are independently defined as follows

Y1 is GEKETPVQKCQRLQIEMNELLN (SEQ ID NO: 26), or

EKETPVQKCQRLQIEMNELLN (SEQ ID NO: 27), or

KETPVQKCQRLQIEMNELLN (SEQ ID NO: 28), or

ETPVQKCQRLQIEMNELLN (SEQ ID NO: 29), or

TPVQKCQRLQIEMNELLN (SEQ ID NO: 30), or

PVQKCQRLQIEMNELLN (SEQ ID NO: 31), or

VQKCQRLQIEMNELLN (SEQ ID NO: 32), or

QKCQRLQIEMNELLN (SEQ ID NO: 33), or

KCQRLQIEMNELLN (SEQ ID NO: 34), or

CQRLQIEMNELLN (SEQ ID NO: 35), or

QRLQIEMNELLN (SEQ ID NO: 36), or

RLQIEMNELLN (SEQ ID NO: 37), or

LQIEMNELLN (SEQ ID NO: 38), or

QIEMNELLN (SEQ ID NO: 39), or

IEMNELLN (SEQ ID NO: 40), or

EMNELLN (SEQ ID NO: 41), or

MNELLN (SEQ ID NO: 42), or

Appl. No.

: 09/782,816

Filed

: February 14, 2001

NELLN (SEQ ID NO: 43), or

ELLN (SEQ ID NO: 44), or

LLN, or

LN, or

N; and

Y2 is VATVISTAR (SEQ ID NO: 45), or

VATVISTA (SEQ ID NO: 46), or

VATVIST (SEQ ID NO: 47), or

VATVIS (SEQ ID NO: 48), or

VATVI (SEQ ID NO: 49), or

VATV (SEQ ID NO: 50), or

VAT, or

VA, or

V, and

derivatives thereof having at least about 90% identity with SEQ ID NO: 1 or SEQ ID NO: 2--

2(Amended). The peptide of claim 1 which is

GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPV[X2]XaaLAKQLAAL  
(SEQ ID NO: 51),

wherein [X2] Xaa is as defined in claim 1.